TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00214604
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg
Study: NCT00214604
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg
Study: NCT03733418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that matched the vitamin D3 color was provided.
Study: NCT00214604
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg
Study: NCT01765478
Drug: HM71224 single ascending dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01765478
Drug: HM71224 food effect
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00223236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching active medication in all other aspects.
Study: NCT00331604
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target dose titration scheme, inhalation.
Study: NCT02499445
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administering remifentanil for anesthesia maintenance
Study: NCT02499445
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administering sufentanil for anesthesia maintenance
Study: NCT00000485
Drug: diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000485
Drug: antihypertensive agents
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00553722
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
Study: NCT00553722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer a placebo tablet orally twice daily for 4 weeks.
Study: NCT04320030
Drug: [18F]-DPA-714 PET/CT scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretherapeutic \[18F\]-DPA-714 PET/CT scan
Study: NCT03602560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
Study: NCT00877799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo administered the day after surgery (Day 1)
Study: NCT00877799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo administered immediately after surgery (Day 0)
Study: NCT03747341
Drug: Placebo - Parts A + B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline for IV administration was used as placebo matching the buprenorphine formulation and administration.
Study: NCT03747341
Drug: Fentanyl - Part A
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participant received up to four fentanyl doses: 0.075, 0.15, 0.25, and 0.35 mg/70 kg in Periods 1 and 2. Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo. Administration of fentanyl was flexible and bolus doses were selected to elicit moderate to more severe respiratory depression with apnoea ≥20 seconds.
Study: NCT03747341
Drug: Fentanyl - Part B
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participant received up to four fentanyl doses: 0.25, 0.35, 0.5, and 0.7 mg/70 kg in Periods 1 and 2.~Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo.
Study: NCT00340574
Drug: AMA1-C1/Alhydrogel + CpG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02216812
Drug: 500 mg vitamin c, 1 pill per day for 6 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02216812
Drug: 1 placebo pill for 6 weeks
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00129311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00595127
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (10mg/kg/day x 4days)
Study: NCT02111265
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure
Study: NCT02111265
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
Study: NCT00649597
Drug: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Normalized name: benazepril hydrochloride / hydrochlorothiazide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/25mg, single dose fasting
Study: NCT00649597
Drug: Lotensin HCT® Tablets 20 mg/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/25mg, single dose fasting
Study: NCT01510457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
Study: NCT02070198
Drug: Long acting FSH and GnRH antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
Study: NCT01569074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 12 weeks
Study: NCT02070198
Drug: Daily FSH and GnRH antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
Study: NCT02880956
Drug: placebo for ABBV-8E12
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo solution for intravenous (IV) infusion
Study: NCT00080925
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00080925
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00545493
Drug: i.v. immunoglobulins
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
Study: NCT01833897
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
Study: NCT00703261
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
Study: NCT02989467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one placebo tablet daily for 5 consecutive days.
Study: NCT01771809
Drug: 75mg SHP647 (PF-00547659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg sterile liquid injected subcutaneously every 4 weeks.
Study: NCT02634645
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical substances are used to treat cancer
Study: NCT03490539
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablet
Study: NCT01215929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
Study: NCT02776748
Drug: FTC/TDF PrEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
Study: NCT00003296
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04088630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral placebo pill within 24 hours of symptom onset
Study: NCT00057980
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00866008
Drug: Ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
Study: NCT02604537
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
Study: NCT04810728
Drug: Extract Psidii guava
Normalized name: guava extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Capsule Extract Psidii guava, three times daily
Study: NCT03470532
Drug: buccal infiltration of 4% Articaine with Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge
Study: NCT03470532
Drug: buccal infiltration of 2% Mepivacaine with Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
Study: NCT02793856
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To deplete Tregs before collecting peripheral blood
Study: NCT03390101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54.
Study: NCT03175029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally twice per day after meals, for 12 weeks.
Study: NCT00102778
Drug: GW873140
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02527200
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
Study: NCT06365762
Drug: EDTA Ophthalmic Solution 2.6%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06365762
Drug: EDTA Ophthalmic Solution 1.3%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02171910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
Study: NCT03740893
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle.
Study: NCT02654964
Drug: Combination Drug Therapy
Normalized name: BILE THERAPY DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent
Study: NCT02350751
Drug: MEDI8852
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02350751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03315754
Drug: TOOKAD Soluble 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular targeted photodynamic therapy using TOOKAD Soluble
Study: NCT01271582
Drug: Irinotecan, 5FU, leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI regimen every 2 weeks \[irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)\]
Study: NCT03859973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT03842982
Drug: HIPEC
Normalized name: Hyperthermic Intraperitoneal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~* 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~* The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours.
Study: NCT01331213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT01160419
Drug: Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m², 1-2-hour-Infusion, day 1
Study: NCT01160419
Drug: 5-FU 2600 mg/m², 24-hour-Infusion, day 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2600 mg/m², 24-hour-Infusion, day 1
Study: NCT04015375
Drug: ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel
Study: NCT01369329
Drug: Group 1: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=intravenous use, in a single dose.
Study: NCT03206788
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
Study: NCT02811523
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin by In Vivo Lung Perfusion
Study: NCT00650481
Drug: Ditropan XL® Tablets 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4x5mg, single dose fasting
Study: NCT00645255
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo one capsule daily
Study: NCT00335985
Drug: Placebo of GB-0998
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL/kg per day is intravenously administered for five successive days
Study: NCT00884767
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00884767
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00884767
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00940472
Drug: DMMET-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
Study: NCT02163278
Drug: DBPR108
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
Study: NCT02163278
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
Study: NCT00838864
Drug: ceftrioxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg iv q12h for 3 days
Study: NCT00838864
Drug: ceftrioxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg q12h for 7 days
Study: NCT03782831
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection every 2 weeks
Study: NCT00779259
Drug: Theophylline 300mg
Normalized name: THEOPHYLLINE 300MG TAB
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
Study: NCT00779259
Drug: Theophylline 300 mg
Normalized name: theophylline 300 MG
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
Study: NCT00567255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04678076
Drug: Ketoprofen Lysine
Normalized name: ketoprofen lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
Study: NCT04678076
Drug: Ketoprofen Oral Product
Normalized name: ketoprofen Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
Study: NCT02969473
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle.
Study: NCT04925531
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
Study: NCT01565343
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 370MBq (10mCi)
Study: NCT02946931
Drug: Prizbind®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizbind®
Study: NCT02316743
Drug: Levothyroxine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: T4 supplementation for heart failure patients with subclinical hypothyroidism.
Study: NCT01591902
Drug: Placebo-Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mL vials
Study: NCT00892840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 0 mg, Once daily, 14 days
Study: NCT00213694
Drug: docetaxel and celecoxib
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00219895
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02086032
Drug: 1mg 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparing sleeping quality between micronized progesterone and dydrogesterone users.
Study: NCT01455909
Drug: ITCA 650 60 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: exenatide in DUROS
Study: NCT02058823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.